Revolution Medicines, INC Schedule 13G passive stakes

Baker Bros. Advisors LP and affiliated entities have disclosed beneficial ownership of 11,443,357 shares, representing 5.3% of Revolution Medicines, Inc.'s outstanding common stock as of June 30, 2026.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 6.4% of Revolution Medicines, Inc. common stock.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5.1% of Revolution Medicines, Inc. common stock as of June 30, 2026.

Janus Henderson Group plc has reported a beneficial ownership of 4.9% of Revolution Medicines, Inc. common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in REVOLUTION Medicines Inc following an internal realignment.

Wellington Management Group LLP and its affiliates reported a 3.6% beneficial ownership stake in Revolution Medicines, Inc. common stock as of December 31, 2025.

Farallon Capital Management entities updated their beneficial ownership in Revolution Medicines, Inc., disclosing a 7.5% stake and internal management changes.

Janus Henderson Group plc has reported a 6.1% beneficial ownership stake in Revolution Medicines, Inc., holding over 11 million shares.

FMR LLC and Abigail P. Johnson have reported a 5.0% beneficial ownership stake in Revolution Medicines Inc. common stock as of September 30, 2025.

Baker Bros. Advisors LP and its affiliates have reported a 5.0% beneficial ownership stake in Revolution Medicines, Inc., totaling 9,364,972 shares of common stock.

Janus Henderson Group plc has reported a 5.7% beneficial ownership stake in Revolution Medicines, Inc., holding over 10.5 million common shares.

Wellington Management Group LLP and its affiliates reported a 5.5% beneficial ownership stake in Revolution Medicines, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Revolution Medicines Inc., holding 8,399,214 shares of common stock as of June 30, 2025.

Farallon Capital and its affiliated entities have disclosed a beneficial ownership of 7.9% in Revolution Medicines, Inc. common stock, totaling 13,262,045 shares, in a Schedule 13G/A filing that was submitted late due to an administrative error.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 11,331,045 shares, representing approximately 6.8% of Revolution Medicines, Inc.'s common stock, noting a late filing due to administrative error.

Farallon Capital and its affiliated entities have filed a Schedule 13G, disclosing a collective beneficial ownership of 5.1% of Revolution Medicines, Inc.'s common stock, with the filing noted as late due to an administrative error.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing its beneficial ownership of 5.5% of Revolution Medicines, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group plc has disclosed a 5.2% beneficial ownership stake in Revolution Medicines, Inc., held for investment purposes in the ordinary course of business.